Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Dec 6, 2022; 10(34): 12587-12593
Published online Dec 6, 2022. doi: 10.12998/wjcc.v10.i34.12587
Table 1 Comparison of total effective rate between the two groups (n, %)
Group
Sample
Basic recovery
Significantly effective
Effective
Not effective
Total effective rate
Control group4516129837 (82.22%)
Treatment group45181510243 (95.56%)
χ2 value4.050
P value0.044
Table 2 Comparison of WAB, Frenchay Dysarthria Assessment Scale, and GQOLI-74 scores between the two groups
GroupWAB scoring
GQOLI-74 scoring
Frenchay Dysarthria Assessment Scale scoring
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
Control group36.42 ± 5.7153.16 ± 7.57248.82 ± 32.28307.53 ± 37.266.46 ± 0.858.51 ± 1.13
Treatment group36.27 ± 5.6462.49 ± 9.13248.13 ± 32.43341.57 ± 43.196.31 ± 0.8311.29 ± 1.62
t value0.1255.2770.1014.0030.8479.442
P value0.901< 0.0010.920< 0.0010.399< 0.001
Table 3 Comparison of speech function grades between the two groups
GroupGrade 1
Grade 2
Grade 3
Grade 4
Grade 5
Pre-treatment, %
Post-treatment, %
Pre-treatment, %
Post-treatment, %
Pre-treatment, %
Post-treatment, %
Pre-treatment, %
Post-treatment, %
Pre-treatment, %
Post-treatment, %
Control group (n = 45)13 (28.89)5 (11.11)a23 (51.11)13 (28.89)a6 (13.33)11 (24.44)a3 (6.67)14 (31.11)a0 (0)2 (4.44)a
Treatment group (n = 45)14 (31.11)0 (0)a b21 (46.67)2 (4.44)a,b7 (15.56)17 (37.78)a,b2 (4.44)19 (42.22)a,b1 (2.22)7 (15.56)a,b